NCT06202417Completed
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
Source: ClinicalTrials.gov · Last updated 11 Jan 2024
Brief summary (registry, in English)
Fruquintinib is an oral tyrosine kinase inhibitor (TKI), which improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we explore the real-world treatment patterns of fruquintinib in the third- or late-line setting for mCRC in six centers in China.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 520 (actual)
- First submitted
- 1 Jan 2024
- Start date
- 1 Jan 2021
- Primary completion date
- 30 Jun 2022
- Lead sponsor
- Fudan University
- Diseases
- Colorectal cancer, Childhood cancers
- NCT number
- NCT06202417
What you commit to
- Study type: Observational
- Participants enrolled: 520
- From 1 Jan 2021 to the primary completion date, 30 Jun 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- (1) lack of follow-up data; (2) fruquintinib administration as second-line treatment; (3) fruquintinib administration stopped after less than two cycles.
Who the study is looking for
- (1) histology-confirmed metastatic CRC (mCRC); (2) disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab; (3) fruquintinib administered as salvage treatment; (4) available clinical data.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongshan Hospital,Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.